A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-muscle Invasive Bladder Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell carcinoma high-grade subtype
    2. Currently eligible for intravesical BCG therapy
    3. BCG-naive disease

You may not be eligible for this study if the following are true:

    1. Prior BCG treatment or known hypersensitivity to BCG
    2. Concurrent use of other investigational agents
    3. History of or evidence of muscle-invasive, locally advanced, metastatic and/or extravesical bladder cancer or any other cancer within the past 5 years



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.